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ABSTRACT 
Neuroleptic malignant syndrome (NMS) is an uncommon but potentially serious 
idiosyncratic response to neuroleptic antipsychotics. It usually affects young males, 
but the risk has been seen to increase with certain factors including the administration 
practices of antipsychotic neuroleptics in these individuals. Even though no predictors 
for NMS are yet known, this article highlights the findings on certain risk factors as 
seen from a series of fifteen patients who developed NMS. Cautious use of neuroleptics 
in those at risk, early recognition and institution of immediate management is important, 
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Neuroleptic Malignant Syndrome (NMS) 
(Delay & Dcniker, 1968) is a rare, but 
potentially life threatening idiosyncratic 
reaction to neuroleptics and other drugs 
affecting dopaminergic transmission. 
The syndrome tends to develop when 
neuroleptic treatment is initiated, or the 
dosage is rapidly increased, particularly when 
the dosage is high or parenteral. It mosdy 
affects young males (Rbadi et al, 2000). 
F.stimation of the frequency of NMS in 
prospective studies range from 0.07%-0.2% 
(Gclcnbcrg et al., 1988; Caroff & Mann, 
1993) to 2.2% (Hcrmcsh et al., 1992; Keck 
et al., (1989a). Pathogenesis of NMS is 
mainly attributable to dopamine blockade 
(Caroff & Mann, 1993; F.badi et al., 1990; 
Hciman Patterson, 1993), and dysregulatcd 
sympathetic nervous system hyperactivity is 
responsible for most features of NMS 
(Gurrera, 1999). NMS may present suddenly 
but more often the course is indolent, with 
autonomic hyperactivity and unexplained 
episodic tachycardia and blood pressure 
fluctuations observed early (Vclamoor et al., 
1994). Altered consciousness is considered 
by some to be sine qua non for the 
diagnosis of NMS (Adityanjcc and Chawla 
1989). 
In a review of 53 patients of NMS, 
Levenson (1985) found that 50 of them 
were receiving neuroleptics, many for a 
long time without any history suggestive of 
previous NMS. Nearly half of the patients 
received anticholinergic drugs and about 
20% were taking lithium. NMS occurred 
in 3 patients without any described exposure 
of neuroleptics Toru et al., 1981). NMS 
can occur in patients on atypical 
antipsychotics and resembles "classical" 
NMS (Hasan and Buckley, 1998). Cases 
of NMS have been attributed to clozapine 
(Reddig et al.,1993; Sachdev et al.,1995), 
and to risperidone (Bonwuk et al., 1996; 
Gleason & Conigliaro, 1997). 
Metaclopromide, prochlorperazine, and 
droperidol are all frequently used 
dopamine antagonists and NMS has also 
been attributed to all (Caroff and 
Mann, 1993). 
Agitation and dehydration in patients 
on neuroleptics increases the likelihood 
to the development of NMS. In fact any 
central nervous system compromise may 
increase the risk of developing NMS, as 
also the morbidity and mortality 
associated (Modestin et. al, 1992; Rosebush 
& Stuart, 1989). 
Differential diagnosis is of prime impor-
tance in any patient suspected to have NMS. 
Conditions which have to be ruled out 
include i) Infection plus neuroleptic side 
effects, ii) anticholinergic toxicity, iii) lithium 
toxicity, iv) catatonia, v) ledial catatonia, vi) 
malignant hyperthermia, vii) heat stroke, 
viii) status epileptics and ix) serotonin 
syndrome. 
Discontinuation of the causative agent 
is the primary treatment of NMS. In 
addition specific drug treatment such as 
bromocriptine and/or dantrolene are 
frequently used. Mortality from NMS is 
high but most reports put the range be-
tween 10-20% (Shalev et al, 1989). 
Here we report on some of the factors 
that appear to predispose subjects to devel-
opment of NMS. The aim of reporting our 
findings is to emphasize the risk factors 
leading to NMS. 
MATERIAL AND METHOD 
Patients who developed fever, rigidity 
and mental status changes rapidly or sud-
denly during concurrent psychotropic (mainly 
neuroleptics) medication use, and where the 
clinical features could not be fully explained 
by any other medical condition, were 
screened as potential NMS suspects. 
Neuroleptic malignant syndrome was con-
firmed in patients fulfilling Levcnson's cri-
teria (1985), which comprises three major 
and six minor manifestations. The major 
manifestations are i) fever, ii) rigidity and 
iii) elevated creatine phosphokinase level. 
The minor manifestations arc 1) tachycardia, 
ii) abnormal blood pressure, iii) tachypnea, 
iv) altered consciousness, v) diaphoresis 
and vi) leukocytosis. The presence of all 
three major, or two major and four minor 
manifestations, supported by clinical history, 
indicates a very high probability of the 
presence of NMS. 
We documented 15 episodes of NMS in 
15 patients admitted to our hospital, in a 
prospective study, over a period of 48 
months (from October 1997 to October 
2001). Thrirtcen of these 15 patients were 
referred and were not on treatment from 
our hospital. 
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TABLE I : Age & Sex Distribution on Patients 
Sex  Range 
(in years) 
Mean 
(in years) 
MALE (n=12) 
Female (n=3) 
All patients (N=15) 
24-65 
21-57 
21-65 
41.4±11.1SD 
39.0±25.5 SD 
41.0± 13.0 SD 
TABLE 2 : Primary Psychiatric Illness & Associated Conditions 
Primary Psychiatric 
Diagnosis 
TABLE 3 : Clinical Features on NMS 
Symptoms  Percent 
Cases (N=15) 
Hyperthermia 
Rigidity 
Elevated CPK Levels 
Altered sensorium 
Unconsciousness 
Delirium 
Labile Pulse Rate 
Sustained Hypertension 
labile Bood Pressure 
Tachypnea 
Diaphoresis 
Tremors 
100%(15/15) 
10O%(15/15) 
100%(15/15) 
100% (15/15) 
(12/15) 
( 3/15) 
100%(15/15) 
13.3% (2/15) 
86.7%(13/15) 
26.6%(4/15) 
26.6%(4/15) 
93.3%(U/15) 
Percentage 
Cases (N=15) 
Mood Disorder 73.4%(11/15) 
Bipolar mood disorder 66.7% (10/15) 
Recurrent depressive episode 6.7%(1/15) 
(depressive episode with psychotic features) 
Alcohol withdrawal 13.3%(2/15) 
Poorly Described 13.3%(2/15) 
Secondary associated diagnosis Diabetes Mellitus 13.3%(2/15) 
Alcoholic liver disease-cirrhosis with portal hypertension 6.7%(1/15) 
Ischemic Heart Disease 6.7%(1/15) 
Infection (Enteric) 13.3%(2/15) 
Lithium Toxicity 6.7%(1/15) 
Mean duration 
(in days) 
14.115.7 SD 
13.0±4.8 SD 
13.2±3.9 SD 
13.8±4.1 SD 
13.6±6.27 SD 
8.0 
14.1±6.3 SD 
13.5±3.5 SD 
14±6.1 SD 
12.5±4.4 SD 
Informed consent from the attending 
and legally responsible relative(s) was ob-
tained as per the norms of our hospital, 
specifically to carry out (i) a full assessment 
of the patient, (ii) for all necessary inves-
tigations and (iii) for treating the patient. In 
addition permission to use the data on 
clinical findings for scientific analysis was 
also taken. This was neither an incidence 
nor a prevalence study, and there might have 
been cases lost to documentation. Diag-
noses of the primary psychiatric illness was 
made separately and independently by two 
consultant based on the history and available 
medical records and ICD-10 criteria. Medical 
diagnoses if any, were based on the opinion 
of the attending consultant. All patients 
underwent necessary laboratory examination 
i.e. a full haemogram, renal function test, 
liver function test, CSF examination, ECG, 
chest X-ray, cultures of blood and urine etc. 
EEG and serum lithium estimation were 
possible only in four patients each. Altered 
sensorium was assessed clinically, also using 
the Glasgow Coma Scale. Dehydration 
considered to be an important factor in the 
pathogenesis of NMS, was said to be 
present, if the following conditions were 
met (1) a 40% or greater decrease in serum 
level of BUN and (2) a 50% or greater 
decrease in serum creatinine concentration, 
taken from the time of admission. These 
were recorded as within normal range in 
all patients on full recovery. Lithium toxicity 
was defined as a serum blood level of or 
greater than 1.5 MEq/L. 
Table 1 shows the age and sex distribu-
tion of our patients. There were 12 male 
patients with a mean age of 41.4 (± 11.1) 
years (range of 24-65 years), and 3 female 
patients with a mean age of 39.0 (± 25.5) 
year (range of 21-57). The overall mean age 
was 41.0(± 13.0) years (range 21-65 years). 
The primary psychiatric diagnosis was 
established from the available history and 
treatment records and based on ICD-10 
classification. Mood disorder was the 
commonest psychiatric diagnosis, seen in 
73.4% (11 of 15) patients with bipolar 
mood disorder present in 66.7% (10 to 15) 
patients. 
Recurrent depressive episode was 
diagnosed in a patient, alcohol withdrawal 
syndrome was seen in two patients and in 
another two patients a correct psychiatric 
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TABLE 4 : Medication when patients developed NMS 
Medication 
Antipsychotic* 
Halnperidol 
Chlorpromazinc 
Thioridazine 
Fluphenazine 
(in 3 weeks time) 
Triflupcrazine 
Clozapine 
Mood Stabilisers 
Lithium 
Carbamazepine 
Antidepressants 
Imipramine 
Fluoxetine 
Others 
Lorazepam 
Diazepam 
Oxazepam 
Trihexiphenidyl 
Clonidine 
Combination Medication 
Neuroleptics+anticholinergic 
Neuroleptics + lithium 
Neurolcptics+lithium+anticholinergic 
carbamazepine 
Neurolcptics+carbamazepine+lithium 
Anticholinetgic + bcnzodiazepinc 
Neuroleptics+benzodiazcpine 
Perceni  : (Cases) 
66.7% (10/15) 
26.6% 
20% 
13.3% 
13.3% 
13.3% 
53.3% 
20% 
13.3% 
6.6% 
53.3% 
40% 
13.3% 
t3.3% 
13..3% 
33.3% 
26..6% 
+13.3% 
13.3% 
6.7% 
6.7% 
(4/15) 
(3/15) 
(2/15) 
(2/15) 
(2/15) 
(8/15) 
(3/15) 
(2/15) 
(V15) 
(8/15) 
(6/15) 
(2/15) 
(2/15) 
(2/15) 
(5/15) 
(4/15) 
(2/15) 
(2/15) 
(1/15) 
(1/15) 
Dosage (mg/day) 
20-80 
150-300 
50-100 
150 
15 
100-300 
900-1200 
600-800 
75-150 
20 
4-6 
10-30 
15-30 
4-6 
0.2-0.3 
TABLE 5 : Duration and Outcome of NMS 
Outcome  Percent cases 
Recovered 
Expired 
80(12/15) 
20(3/15) 
Main Duration 
(days) 
16.7±6.3SD 
12.0±4.6 SD 
diagnosis could not be established although 
they seemed to have been treated for 
psychotic condition. 
No additional active medical illness 
was identified in 53.3%( 8 of 15) patients. 
Of the remaining 46.7% ( 7 of 15) 
patients, two had diabetes mclbtus, one 
each had alcoholic liver disease with 
cirrhosis and portal hypertension, and 
ischemic heart disease. Two patients tested 
positive on widal test and were treated 
for enteric fever. Of die 8 patients receiving 
lithium, serum estimation was done in only 
4, and one patient had lithium toxicity. 
Five features were present in all 15 
patients in our series. There were, (i) 
Hyperthermia with a mean duration of 
14.1 (±5.7) days and a mean peak recording 
of 103.6 (±1.8) "F, peaking at 7.8(±4.04) 
days' (ii) muscular rigidity of all limbs with 
a mean duration of 13.2(±3.9) days and 
mean peak day of 8.2 (±4.8);(iii) Elevated 
CPK levels (5759 U/L), with mean duration 
of 13.2 (±3.9) (iv) altered sensorium with 
a mean duration of 13.8 (±4.1) days and 
(v) a labile pulse rate with mean duration 
of 13.6(±6.3) days. Blood pressure was 
persistendy high in 13.3% ( 2 of 15) 
patients, and labile in 86.7% (13 of 15) 
patients. Tachypnea was present in 26.6% 
(4 of 15) patients and 26.6% (4 of 15) 
patients were diaphoretic Tremors were 
present in 93.3% (14 of 15) patients with 
coarse tremulousness of the trunk and 
extremities in 60% (9 of 15). We can not 
comment on incontinence, as most patients 
had been catheterized before admission. 
While all patients were receiving 
neuroleptics, these had been used for the 
first time in 7 of the 15 patients and 
reintroduced after a drug free period in 
another 7 of 15 patients. Only 1 patient 
developed NMS on a maintenance regimen 
of stable neuroleptic treatment. As can be 
seen from Table 4, six different neuroleptic 
drugs had been prescribed to diese patients. 
Haloperidol (dose range of 20-80 mg/ 
day) the commonest offending agent, was 
administered to 66.7% (10 of 15) patients, 
either alone or in combination with another 
neuroleptic, Chlorpromazine in 26.6% (4 to 
15) patients (dose range of 150-300 mg/ 
day), and Thioridazine was prescribed in 
20% (3 of 15) patients (dose range of 50-
100 mg/day). 13.3% (2 of 15) patients had 
received fluphenazine depot injection (150mg 
in 3 weeks time) and trifluoperazine was 
prescribed in 13.3% (2 of 15) patients (dose 
range of 15-20 mg/day). Clozapine had 
been used in 13.3% (2 of 15) patients in 
the dose range of 100-300 mg/day. 
Various other drugs in combination with 
neuroleptics were given to the patients 
developing NMS. Lithium (900-1200 mg/ 
day) was being taken by 53.3% (8 of 15) 
patients. Serum lithium estimation was 
carried out in 4 of diese 8, and toxic level 
was measured in 1. However, it was not 
possible to discern the exact sequence of 
lithium toxicity with NMS in this patient 
The other mood stabiliser used 
concurrently with neuroleptics was 
carbamazepine in 20% (3 of 15) patients 
(dose of 600-800 mg/day). Strangely, there 
was no patient on sodium valproate, 
which is a commonly prescribed mood 
stabiliser. Other drugs used were 
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anticholinergics i.e. imipramine and 
trihexyphenydyl (2 patients each) 
fluoxetine, while benzodiazepines were 
prescribed to all. 
Furthermore, 40% (6 of 15) patients 
were receiving two or more neuroleptics in 
combination, of which at least one was by 
parenteral route. 33.3% (5 of 15) patients 
were receiving neuroleptics plus an 
anticholinergic; 26.6% (4 of 15) patients a 
neuroleptic plus lithium; 13.3%( 2 of 15) 
were receiving neuroleptics plus lithium plus 
carbamazepine plus anticholinergics; 6.7% 
(1 of 15) an anticholinergic plus 
benzodiazepine and another 6.7% (1 of 15) 
a neuroleptic plus benzodiazepine combina-
tion. In 6.7%( 1 of 15) patients, there was 
history of abrupt neuroleptic withdrawal 
preceding NMS. 
There were 3 (20%) deaths in 15 patients 
who developed NMS in our series. Mean 
duration of syndrome in patients who 
expired was 12.0(±4.6) days. However, 80% 
(12 of 15) patients recovered fully after a 
mean duration of 16.7 (± 6.3) days. Fol-
lowing recovery a neuroleptic of a different 
class was safely reintroduced in 4 patients, 
who were required to be treated. There 
pwas no recurrence of NMS in these 4 
patients on a follow-up of six months. 
DISCUSSION 
Despite a considerable increase in the 
recognition of NMS, risk factors predisposing 
to this pothentialy fatal condition are 
frequently ignored. Our study intends to 
highlight some of these risk factors. 
The male of female (M:F) ratio of 
patients in our sample was 4:1, a mean 
age of 41 (±13.0) years, mean rime to full 
recovery was 16.7(±6.3) days and a mortal-
ity of 20%. In a recent study from India, 
Chopra & Raguram (2001) reported a 
M:F ration of 3:1 a mean age of 29.5(±9.9) 
years, mean time to full recovery for those 
,!f\vho recovered 13 (±7.5) days and mortality 
ot 38.5%. In keeping with the earlier 
suggestions that NMS is commoner in 
males, our data also shows a made 
preponderance though not exactly in die 
young We found a higher mean age in our 
sample, which is probably reflective of the 
age trend of the primary psychiatric disorder 
in our patients. 
All 15 patients were receiving neuroleptics, 
but these were newly introduced in 7 of 
15 cases and the dose increased rapidly in 
11 of 15 Patients. In one patient, NMS 
followed abrupt withdrawal of neuroleptics. 
Neuroleptics were administered parentally 
in 40% patients, and 40% patients received 
a combination of 2 or more neuroleptics. 
These findings together with neuroleptic 
dosages used as shown in table IV suggest 
that rather man the total daily dose of the 
neuroleptics, it is (i) the parental adminis-
tration of neuroleptics, (ii) a rapid increase 
of dose (iii) a combination of neuroleptics, 
and (iv) new exposure, along with other non 
pharmacological factors, that probably act 
as the risk for NMS. The use of IV/IM 
medication is tantamount to using higher 
oral dose since parentral anti-psychotics 
have a greater bio-availability than an 
equivalent oral dose. Beradi et al (1998) and 
Rosebush & Steward (1989) have also iden-
tified risk indicators in their studies which 
support our observations. While early re-
ports suggest no relationship between new 
exposure to neuroleptics and the occurrence 
of NMS, in our series, nearly half had 
received neuroleptics for the first time. This 
finding may reflect upon the trait vulner-
ability of these patients for developing 
NMS. The handful of studies carried out 
(Iwahashi, 1994; Ram et al., 1995) have 
failed to identify any genetic defects causally 
related to NMS. Considering the many 
clinical features shared by NMS and 
malignant hyperthermia, it seems reasonable 
to hypothesise that similar but distinct 
mutations of a heterogeneous group of 
regulatory proteins might also form some 
basis of vulnerability to develop NMS 
(Gurrera,- 2000). 
Neuroleptic withdrawal can cause 
autonomic and behavioural symptoms (nau-
sea, vomiting, diarrhoea, diaphoresis, myalgia, 
anxiety, restlessness) and movement disor-
der (withdrawal emergent parkinsonism, 
withdrawal dyskinesia, covert dyskinesia). 
Withdrawal NMS is a rarer condition with 
only 7 cases reported to date. The 
pathophysiology of withdrawal medical 
symptoms may be related to cholinergic 
rebound. Withdrawal NMS may be attributed 
to an "imbalance" in the dopaminergic 
systems. In our series, 1 case was related 
to abrupt withdrawal of neuroleptics. The 
abrupt withdrawal of dopaminergic drugs 
have also produced an NMS-likc condition 
in patients with Huntington disease and 
Parkinsonism (Ebadi et al.,1990). 
Implicated drugs include levodopa, 
bromocriptine, and amantadine. NMS 
has also been associated with abrupt 
withdrawal of anticholinergic agents. It is 
suggested that simultaneous withdrawal 
of both anticholinergic and ncurolepitc 
medication, mainly long acting 
neurolepitcs, seems to be a risk factor 
for NMS (Spivak et al., 1990). 
A strinking finding from our data is 
that majority of patients had a mood 
disorder, Affective illness has been 
described as a risk factor for NMS 
(Addonizio et al.,1986; Gurrea,1999; 
Rosebush & Stewart,1989). Interestingly 
60% patients in our scries were being 
treated for extreme agitation when NMS 
developed. However, agitated patients are 
more likely to receive a higher dose of 
potent antipsychotics. Aho, psychomotor 
overactivity leads to physical exhaustion 
and dehydration (Harsch, 1987). It may 
not be possible to delineate the independ-
ent risk associated with each of these 
factors. Either factor alone, or in com-
bination may predispose to NMS. Several 
authors (ltoh et al., 1977; Keck et al., 
1989b; Rosebush & Stewart, 1989) have 
commented on the remarkably frequent 
occurrence of psychomotor agitation 
and/or excitement before development of 
NMS, such that this must rank as a 
highly reliable risk factor in association 
with neurolepitc treatment. In our series 
53.3%( 8 of 15) patients were dehydrated. 
Dehydrariion in NMS can have different 
reasons. Diaphoresis is common in NMS 
with rates varying from 50% to 100% 
(Mann et al., 1991; Rosebush et al., 1989). 
In contrast to its role in true fever, 
diaphoresis in NMS is not part
 %of a 
coordinated effort to lower temperature, 
and excessive sweat gland activity is prob-
ably responsible for associated dehydration, 
which may contribute to hyperthermia. 
Whether primary or secondary feature of 
the illness, dehydration may contribute to 
the development of fulminant NMS by 
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increasing the effective concentrations of 
neuroleptics in extravcascular fluids 
(Rosebush & Stewart, 1989; Sachdev et al., 
1997). Proper hydration and good support-
ive care can perhaps reduce the mortality 
in NMS. Tachycardia and tachypnea in NMS 
reflect a hypcr-adrcncrgic state, but increased 
metabolism makes additional 
cardiopulmonary demand. Urinary 
uncontinence is another clinical manifes-
tation of autonomic dysfunction. 
Majority of our (8 of 15) patients were 
taking lithium, raising the important 
question of relationship of lithium with 
NMS. It has been suggested that lithium 
may predispose to NMS by rendering 
the brain more vulnerable to neuroleptic 
side effects (Addonizio, 1985). In addition 
lithium can cause diabetes insipidus lead-
ing to increase in neurolepitc concentra-
tion. Lithium toxicity in itself is not 
associated with fever. Typically it pro-
duces weakness, lethargy, cerebellar dys-
functions, facilitation, myoclonus and 
seizures, a clinical picture quite easily 
distinguishable from NMS. From amongst 
8 patients who were receiving lithium 
when they developed NMS, lithium 
toxicity was picked up in 1. Increased 
random blood sugar with hyperosmolar 
state was another finding in 1 patient. 
Clinicians should not be reluctant to 
make a diagnosis of NMS in presence of 
an infection, as they often coexist. 
Infection may predispose subjects to NMS 
by producing dehydration. Conversely, NMS 
may create a setting for infection as a result 
of respiratory compromise, immobility and 
urinary catheterization (Rosebush & 
Stewart, 1989). Urine infection in 1 of 
the 15, and enteric infection in 13.3% 
(2 of 15) patients were identified our 
series. I-cft lower zone infiltration on 
chest X-ray was found in one. However, 
the role of these infections as risk in 
development of NMS is not clear. 
The most common serious complica-
tion of NMS is rhabdomyolysis, due to 
an acute, diffuse breakdown of muscle 
tissue. It produces extremely high serum 
creatine phosphokinase levels, 
hyperkalemia, myoglobinuria and acute 
renal insufficiency. 
All patients received supportive 
treatment in an intensive care unit. 
Bromocriptine was used in 80% (12 of 15) 
with a mean dose of 11 mg/day. No 
patient was given dantrolene. In keeping 
with previous observations of Rosebush 
& Stewart (1989), our data suggests that 
the pattern of illness in NMS tends to 
follow the natural course regardless of 
treatment. 
Shalev et al (1989), found no signifi-
cant difference in mortality due to NMS 
in those who received only supportive 
care, and those who received a specific 
medication such as bromocriptine, 
dantrolene or amantadine, alone or in 
combination. These findings suggest that 
specific treatment may have little or no 
effect in reducing mortality in patients 
with NMS. In our opinion good intensive 
care and discontinuatioin of neuroleptics 
at the earliest are more likely to save the 
patient's life. 
CONCLUSIONS 
Based on the findings of this small series 
of neuroleptic malignant syndrome, we 
conclude that NMS, has increased likelihood 
of developing in those individuals who are 
receiving neuroleptic medications. The nature 
of their psychiatric illness seems to be 
mostly a affective disorder where a 
combination of different neuroleptics, and/ 
or neuroleptics with mood stabilisers are 
given. The route of administration is more 
likely to be parentral with a rapid upward 
dose titration. The presence of agitation, 
dehydration, systemic infections, 
compromised brain functions and the male 
sex are somehow more common 
associations. The early presence of auto-
nomic dysregulation and development of 
hyperthermia and rigidity warrant immedi-
ate cessation of neuroleptic and psychotropic 
medication and institution of supportive 
care. NMS is a life threatening condition, 
and wc maintain that in atl patients exhib-
iting potential risk factors, caution should 
be exercised in the use of neuroleptics. 
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